In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Hereditary Angioedema Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight ...

RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today reported ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust (“DRI”) for up to $179 million, comprised ...

Background: Kallikrein-1 is a serine protease expressed in multiple tissues including the kidney, where it is secreted into the urine. Low urinary kallikrein levels are associated with essential ...

Intellia Therapeutics fell 20.5% the day after it reported Phase 2 test results for a promising treatment. Explore more ...

NTLA-2002, which leverages the CRISPR/Cas9 technology, is expected to provide a one-time treatment by inactivating the kallikrein B1 (KLKB1) gene responsible for producing prekallikrein ...

They found that both dosages led to a reduction in angioedema attacks as well as a sustained and meaningful reduction in kallikrein levels in HAE patients. "This reduction is perhaps the most ...

NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1). A single dose of NTLA-2002 may provide lifelong control of angioedema attacks. In this phase 2 portion of a phase 1–2 trial ...

Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of the disease and edited a gene in the livers of nonhuman primates ...

Opens in a new tab or window A single dose of the CRISPR-based gene-editing therapy NTLA-2002 reduced angioedema attacks and led to sustained reduction in total plasma kallikrein protein levels ...

They found that both dosages led to a reduction in angioedema attacks as well as a sustained and meaningful reduction in kallikrein levels in HAE patients. "This reduction is perhaps the most ...